Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




MicroPulse Technology Spares Tissue in Eye Surgeries

By HospiMedica International staff writers
Posted on 30 Aug 2010
A new short pulse dosing technology offers fine control of the characteristics of visible light laser systems, allowing tissue sparing eye surgeries.

The MicroPulse technology is based on Tissue Sparing Photocoagulation (TSP), a controlled laser dosing approach that limits the time laser-induced heat can to spread to adjacent tissues, thus providing fine control of energy delivered; at the same time, TSP sets longer intervals between pulses, enabling cooling to take place before the next pulse is delivered. More...
The technology is intended for use in patients suffering from proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), extrafoveal, juxtafoveal and some types of subfoveal retinal neovascularization (SRNV), and other sight-threatening retinal and glaucoma disorders. In clinical studies, the system has demonstrated favorable outcomes and significantly less damage to healthy retinal structures compared to traditional continuous wave laser treatment.

The heart of the system is a diode pump source, which powers a frequency doubled solid-state visible laser, producing a pulsed laser output with a train of pulses with on times of 25-10,000 microseconds. System resources provide instructions to the diode pump for the creation of the pulsed output, with on and off times that provide for substantial confinement of thermal effects at the target site. This results in TSP without photocoagulation damage to any of the adjacent tissues, and without causing full thickness retinal damage and associated vision loss. MicroPulse technology was developed by Iridex (Mountain View, CA, USA).

"Extending our MicroPulse technology from our infrared laser systems to our visible laser systems … is important because the majority of lasers sold today are visible wavelength laser systems,” said Theodore Boutacoff, President and CEO of Iridex. "It is our profound belief that lasers that support TSP can provide greater benefits to patients than lasers have in the past, and consequently lasers will remain the standard of care for the treatment for many ocular disorders.”

Laser photocoagulation (PC) is the current standard of care for the treatment of retinal diseases. Most of these treatments have been conducted with visible light lasers (green and red lasers), and all of these laser treatments are based upon obtaining a visible endpoint as the optimal tissue reaction, which becomes visible during the laser treatment. These laser pulse widths are typically 50 ms - 300 ms. The energy is absorbed by chromophores such as melanin or blood, and is conducted away from the absorbing or pigmented layers into adjacent nonabsorbing and nonexposed layers, thus causing thermal damage laterally and axially into the clear layers, in addition to the pigmented layers.

Related Links:
Iridex



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.